2Hann HW, Fontana RJ, Wright T, et al. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis.Liver Transpl, 2003, 9: 49-56.
3Oh JM, Kyun J, Cho SW. Long-term lamivudine therapy for chronic hepatitis B in patients with and without cirrhosis. Pharmacotherapy,2002, 22: 1226-1234.
4Villeneuve JE Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology, 2000, 31: 207-210.
5Yao FY, Terrault NA, Freise C, et al. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation:a comparative study using a matched, untreated cohort. Hepatology,2001. 34:411-416.
6Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol, 2000, 33: 301-307.
7Kapoor D, Guptan RC, Wakil SM, et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol,2000, 33: 308-312.
8Liaw YF, Sung JJ, Chow WC, et al. Lamivdine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med, 2004,351: 1521-1531.
9Hanada S, Kumashiro R, Kaji R, et al. Additional benefit of lamivudine treatment as a preventive therapy for hepatic encephalopathy in patients with decompensated liver cirrhosis associated with hepatitis B. Int J Mol Med, 2002, 10: 647-648.
10Perrillo RP, Wright T, Rakela J, et al. A multicenter United StatesCanadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology, 2001, 33:424-432.
